Is Visceral Fat Involved in the Pathogenesis of the Metabolic Syndrome? Human Model

Authors

  • Michael D. Jensen

    Corresponding author
    1. Endocrine Research Unit, Division of Endocrinology, Metabolism and Nutrition, Mayo Clinic, Rochester, Minnesota
    Search for more papers by this author

Endocrine Research Unit, Mayo Clinic, 200 First Street SW, Rm 5-194 Joseph, Rochester, MN 55905. E-mail: jensen@mayo.edu

Abstract

Objective: To review the evidence for and against the role of visceral adipose tissue as a major contributor to the metabolic complications of obesity through abnormal regulation of lipolysis.

Research Methods and Procedures: Data from investigators in the field who have studied visceral adiposity and metabolic health and/or regional and systemic free fatty acid (FFA) release were considered.

Results: Although visceral fat mass was positively correlated with adverse health consequences and excess FFA availability, visceral fat was not the source of excess systemic FFA availability. Upper body non-visceral fat contributes the majority of FFAs in lean, obese, diabetic, and non-diabetic humans. Increasing amounts of visceral fat probably result in greater hepatic FFA delivery.

Discussion: Systemic, as opposed to hepatic, insulin resistance is unlikely to be caused by high rates of visceral adipose tissue lipolysis.

Ancillary